GLP-1 Agonist Industry News: Ascletis Pharma's ASC47 Combined with ASC31 Shows Significant Weight Loss Without Muscle Loss Effect
Publish Time:
2025-08-22
Guangzhou Congen Pharmatec Co.,Ltd. (CongenPharma), a drug peptide R&D and manufacturing company, shares industry news: On August 18, 2025, Ascletis Pharma (HKEX:1672) in Hong Kong, China, announced that its weight loss candidate drug ASC47, which does not reduce muscle mass, combined with the self-developed GLP-1R/GIPR dual-target agonist peptide ASC31, showed significant efficacy in a diet-induced obesity (DIO) mouse model.
The combination therapy shows outstanding weight loss effects.
- In the diet-induced obesity (DIO) mouse model, after 14 days of treatment with low-dose ASC47 combined with the novel GLP-1R/GIPR dual receptor agonist peptide ASC31, mouse body weight decreased by 44.8%.
- In the DIO mouse model, the efficacy of low-dose ASC47 combined with ASC31 (44.8% weight loss) was superior to low-dose ASC47 combined with tirzepatide (38.1% weight loss), with the difference being statistically significant.
ASC31 is a novel GLP-1R and GIPR dual-target agonist peptide independently developed by Ascletis. It shows good pharmacokinetic characteristics in non-human primates, demonstrates positive in vitro activity, and exhibits favorable in vivo efficacy in DIO mice. ASC31 reflects part of Ascletis' achievements in independently developing new subcutaneous and oral peptides using the Ultra-Long-Acting Platform (ULAP).
ASC47 is a fat-targeting, once-monthly subcutaneous injection thyroid hormone receptor β (THRβ) selective small molecule agonist independently developed by Ascletis. ASC47 has unique differentiated characteristics, enabling it to target fat and produce dose-dependent high drug concentrations in adipose tissue.
Guangzhou Tongjun Pharmaceutical Technology Co., Ltd., a drug peptide R&D and manufacturing company, comments: The excellent performance of ASC31 and ASC47 provides new ideas for peptide-based weight loss drug development, highlighting technological progress in the industry.
Relevant Information
undefined
